Actively Recruiting
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Led by Riboscience, LLC. · Updated on 2025-12-23
150
Participants Needed
3
Research Sites
149 weeks
Total Duration
On this page
Sponsors
R
Riboscience, LLC.
Lead Sponsor
T
Tam Anh Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).
CONDITIONS
Official Title
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years old at the time of signing consent
- Diagnosed with advanced, metastatic, or progressive colorectal cancer
- Have received, been ineligible for, intolerant to, or declined all approved standard treatments for metastatic colorectal cancer
- Documented disease progression based on two scans within 2 to 4 months before study start
- Histologically or cytologically confirmed colorectal cancer diagnosis
- Willing to provide a pre-treatment tissue sample (archival or fresh if archival unavailable)
You will not qualify if you...
- Received any approved anti-cancer therapy (chemotherapy, targeted therapy, immunotherapy, or radiation) within 2 weeks before first study treatment dose, unless recovered to Grade 1 or baseline from prior treatment side effects
- Palliative radiotherapy for bone or soft tissue metastases must be completed more than 7 days before first treatment dose
- Receiving hormone-replacement therapy or oral contraceptives
- Have Grade 2 neuropathy or Grade 2 alopecia
- Evidence of rapid disease progression causing quick clinical decline
- Other malignancies within 3 years before study start, except those with very low risk or treated with curative intent or indolent tumors under surveillance or untreated
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Community Clinical Trials
Kingwood, Texas, United States, 77339
Actively Recruiting
2
Tam Anh TP. Ho Chi Minh General Hospital
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 70000
Actively Recruiting
3
Tam Anh, Ha Noi General Hospital
Hà Nội, Vietnam, 10000
Actively Recruiting
Research Team
R
Riboscience Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here